Nav: Home

New findings concerning hereditary prostate cancer

July 11, 2016

It is a well-known fact that men with a family history of prostate cancer run an increased risk of developing the disease. The risk for brothers of men with prostate cancer is doubled. But a doubled risk of what, exactly? Prostate cancer my be an indolent condition that does not require treatment, or aggressive and fatal. Obviously, it makes a big difference whether a man has an increased risk of developing the indolent or the aggressive form, but until now these different risks have not been known.

The Swedish researchers studied the risk of cancer in over 50,000 brothers of men with prostate cancer. Thirty per cent of the men that had one brother only with prostate cancer were diagnosed with prostate cancer by age 75 years, about double the Swedish national average risk of 13 per cent. Their risk of aggressive prostate cancer was much lower: 9 per cent (national average risk 5 per cent).

In men that had both a father and a brother with prostate cancer, the risk of any form of prostate cancer was as high as 48 per cent; the risk of the aggressive form was 14 per cent.

The researchers also studied how the different risks were affected by the severity of the cancer in an affected brother or father:

"We expected that the risk of aggressive prostate cancer would not be much increased in brothers of men with the indolent form, but it turned out to almost as high as the risk among men with aggressive prostate cancer in the family", says Associate Professor Ola Bratt at Lund University, who lead the research project.

"This is an important finding that needs to be disseminated to the general public and to healthcare professionals. Men whose father or brother have an indolent, untreated prostate cancer are probably not aware that this increases their own risk of developing aggressive prostate cancer. They might not even know that there is prostate cancer in the family", says Ola Bratt.

The study emanates from the research database PCBaSe. The principal investigator of PCBaSe is Pär Stattin, Professor of Urology at the universities in Uppsala and Umeå.
-end-
Publication: "Family History and Probability of Prostate Cancer, Differentiated by Risk Category - a Nationwide Population-Based Study", Ola Bratt, Linda Drevin, Olof Akre, Hans Garmo & Pär Stattin
Journal of the National Cancer Institute online, 2016, July 11, http://www.oxfordjournals.org/our_journals/jnci/for_authors/journal_policies.html

Lund University

Related Prostate Cancer Articles:

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
Prostate cancer discovery may make it easier to kill cancer cells
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
New test for prostate cancer significantly improves prostate cancer screening
A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
More Prostate Cancer News and Prostate Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.